If prostate cancer spreads to other parts of the body, it can become deadly and commonly moves to bones, the lungs, lymph ...

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

With Sir Chris Hoy recently revealing his cancer is terminal, prostate cancer experts tell Lisa Salmon how men can get tested ...

There is no single, diagnostic test. Doctors make a diagnosis based on various measures. This can include a prostate-specific ...

The Olympic cycling legend has been given between two and four years to live but said he was determined to be around for much ...

A prostate cancer specialist has shared seven warning signs of the disease that men should be aware of. Around one in eight ...

Petr Holy, consultant ujsonologist and specialist in prostate cancer diagnosis from Men's Health Clinic in Kingston, has ...

While prostate cancer is typically diagnosed in men aged 70 plus there have dramatic increases in the disease in patients ...

(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of ...

It is the fourth most common cancer seen in men, and it makes up about 4% of all cancer ... where she most recently served as ...

The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk ...

UroGen Pharma has received the NDA acceptance from the US FDA for UGN-102 (mitomycin) to treat bladder cancer.